



Corporate Overview

Innovating to Transform the Lives of Patients and Their Families

September 2026



Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements related to: the company's growth prospects and future financial and operating results, including the company's 2026 financial guidance and the company's expectations related thereto, including with respect to anticipated near-term catalysts and expectations for total revenue growth and double-digit growth for combined rare oncology and epilepsy franchises and Xywav sales; the planned acquisition of Actio and the expected timing of closing of the transaction, and the potential impact on the company's rare epilepsies portfolio; the potential of ABS-1230 to address a significant unmet need in KCNT1+ epilepsy; the upfront and potential milestone payments related to the Actio acquisition; the company's advancement of pipeline programs and the timing of development activities, regulatory activities, approvals, and submissions related thereto; the potential for a near-term commercial launch of Ziihera in 1L HER2+ GEA in the U.S.; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including: the second interim OS data from the Phase 3 HERIZON trial of zanidatamab in 1L GEA, the top-line data from the EmpoweHER-BC-303 trial in breast cancer and top-line data from the Phase 3 ACTION trial of Modeyso in recurrent H3 K27M-mutant diffuse glioma; the company's development, regulatory and commercialization strategy; the company's expectations with respect to its products and product candidates and the potential of the company's products and product candidates and the potential regulatory path related thereto, including Ziihera's potential to become the HER2-targeted therapy of choice in 1L HER2+ GEA, regardless of PD-L1 status and other HER2-expressing cancers; the company's capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the company's ability to realize the commercial potential of its products; the company's net product sales and goals for net product sales from new and acquired products; the company's views and expectations relating to its patent portfolio, including with respect to expected patent protection, as well as expectations with respect to exclusivity; the company's clinical trials confirming clinical benefit or enabling regulatory submissions, including the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of Modeyso in recurrent H3 K27M-mutant diffuse glioma and extend to use in 1L patients; and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Epidiolex/ Epidyolex, Ziihera, Modeyso, Zepzelca and other lead marketed products; effectively launching and commercializing the company's other products and product candidates, including Ziihera in 1L HER2+ GEA; the successful completion of development and regulatory activities with respect to the company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the company's products; the time-consuming and uncertain regulatory approval process, including the risk that the company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the company's business operations and financial results; protecting and enhancing the company's intellectual property rights and the company's commercial success being dependent upon the company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the company's products and product candidates, including due to geopolitical tensions and military conflicts; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired products, product candidates and businesses, including the company's ability to complete the acquisition of Actio on the proposed terms and in a timely manner, or at all and, the company's ability to realize the anticipated benefits of the acquisition; the company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the company's cash flows and capital resources; the company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; fluctuations in the market price and trading volume of the company's ordinary shares; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including the company's Annual Report on Form 10-K for the year ended December 31, 2025 and future filings and reports by the company. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.



Transforming Lives. Redefining Possibilities.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. GAAP, the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation. The company presents non-GAAP ANI (ANL) (and the related per share measure) and certain line item components as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP ANI (ANL) (and the related per share measure) and its line item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow in the Appendix hereto, and in the case of non-GAAP ANI (ANL) (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP ANI (ANL), including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP ANI (ANL) measure.

The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. The company's management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for the company's management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the company in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.



At Jazz, we are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options



Strong Execution Across Franchises Drives 2026 Revenue Guidance Increase

2Q26 Execution Highlights

Commercial:

- **Xywav** (+13% YoY)
- **Epidiolex** (+16% YoY)
- **Zepzelca** (+42% YoY)
- **Ziihera** now approved and launched in 1L HER2+ mGEA

R&D:

- Phase 3 HERIZON-GEA-01 data published in *The New England Journal of Medicine*¹
- **Submitted NDA** for cannabidiol capsule formulation²
- Announced collaboration with AbCellera to discover next-generation TCE multispecific antibodies

Financial Strength

Robust 2Q26:

- **Record quarterly revenues of \$1.2B** (+16% YoY)
- **Double-digit growth**³ from sleep, epilepsy and oncology franchises
- **Raised** full-year 2026 **revenue guidance**

Strong balance sheet:

- Cash⁴ at end of 2Q26: **\$2.2B**
- YTD⁵ operating cash flow: **\$824M**

Upcoming Milestones

- HERIZON-GEA-01 **Arm B OS statistically significant**⁶; results to be presented at an upcoming 4Q26 medical meeting
- Modeyso **ACTION study** data 1H27
- EmpowHER-BC-303 trial enrolling, **data expected** late 2027 / early 2028
- Robust zanidatamab development program **continues to progress**
- Opportunity for additional **business development** in rare disease


¹Shitara et al., The New England Journal of Medicine, May 2026; ²Cannabidiol capsule formulation, if approved, for use within Epidiolex's existing approved indications (LGS, or TSC); ³Double-digit growth based on net product sales, which excludes revenues from high-sodium AG royalties; ⁴Cash includes cash, equivalents, and investments as of June 30, 2026; ⁵For the six months ended June 30, 2026; ⁶Top-line results from the second interim survival analysis for the HERIZON-GEA-01 doublet regimen of zanidatamab + chemotherapy.



Refined Strategic Focus on Rare Disease

Attractive Growth Market That Plays to Jazz's Strengths

**RARE
ONCOLOGY**



**RARE
EPILEPSY**




**RARE
SLEEP**



**NEW RARE
THERAPEUTIC
AREAS**



Rare Disease

-  High unmet need
-  Small patient populations
-  Concentrated call points
-  Differentiated support services
-  Lower competitive intensity
-  Attractive peak revenue opportunity for Jazz
-  Favorable regulatory and policy dynamics

Actio Acquisition: Building on Success in Rare Epilepsies

Jazz to acquire Actio Biosciences expanding rare epilepsies portfolio

- Strong strategic fit that is complementary to Jazz's existing development and commercial expertise in rare pediatric epilepsy; Transaction expected to close by 4Q26
- Adds ABS-1230, a clinical-stage first-in-class genetic precision KCNT1 inhibitor
- KCNT1+ epilepsy is a genetic DEE affecting ~2,500 U.S. patients¹ with no FDA approved therapies

ABS-1230 has potential to address a significant unmet need

- Demonstrated meaningful seizure reductions in early proof-of-concept trials in children with KCNT1 epilepsy
- Received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations and has been accepted into the Rare Disease Evidence Principles (RDEP) process
- Ongoing registrational Phase 1b/2a KYRON trial² to support potential NDA

Transaction Terms

- Includes \$820M upfront payment and up to \$500M in potential approval and sales milestones
- Actio to spin-out new, independent private company with Jazz receiving a minority stake



¹Data on File; ²NCT07600736.



Key Commercial Products

Highly Differentiated Medicines for
Patients with Serious Diseases

Successful Commercial Execution in Rare Disease

20+ years of experience building a diverse portfolio of products that make a difference for patients and their families

Rare Sleep

xywav™ 

Leader in Sleep

Proven commercial capabilities

Xywav remains **#1 branded treatment** for narcolepsy¹

Rare Epilepsy

 Epidiolex®  Epidyolex®
cannabidiol
Oral solution

Expanding Epidiolex development program

Exclusivity into the very late 2030s

Epidiolex is the **#1 branded epilepsy treatment**²

Rare Oncology

 **ZIIHERA®**
(zanidatamab-hrii)
50mg/ml Injection for IV

 **MODEYSO™**
(dordaviprone) capsules
125 mg

 **RYLAZE®**
asparaginase erwinia chrysanthemi
(recombinant)-rywn for injection
10mg/0.5mL per vial

 **ENRYLAZE**

 **ZEPZELCA®**
(lurbinectedin) for injection 4 mg

 **DEFITELIO®**
(defibrotide sodium) injection
80 mg/mL

 **Vyxeos®**
(daunorubicin and cytarabine) 44 mg/100 mg
liposome for injection

¹Based on 2Q26 Xywav net product sales; ²Based on 2Q26 Epidiolex net product sales.

Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity



Cindy

Xywav patient living with IH

Xywav remains the #1 branded treatment for narcolepsy¹

- Benefits of a **highly efficacious and safer** treatment option due to **reduced sodium content** and an **individualized dosing regimen** continue to resonate with patients and HCPs
- **FDA** published its summary of **clinical superiority findings** stating Xywav is clinically superior to Xyrem by **means of greater safety**
- JazzCares services and field nurse educator program **helping patients navigate initiation of Xywav treatment**
- See **most opportunity for patient growth in IH** as the only approved therapy to treat IH and no near-term competition

¹Based on 2Q26 Xywav net product sales.



Epidiolex: Development Opportunities for Durable Growth



Corey

Epidiolex patient living with LGS



Epidiolex is the #1 branded epilepsy treatment¹

- **Expanded Epidiolex development opportunities** with multiple new clinical trials
- Submitted NDA for **cannabidiol capsule formulation²** to help broaden utilization and increase flexibility for patients
- **Further data generation**, including **beyond-seizure benefits** from the EpiCom³ study in TSC and nurse-reported responses to the BECOME⁴ caregiver survey in long-term care facilities
- **JazzCares** suite of services including the **Nurse Navigator program** helps patients, families, and HCPs navigate treatment-related topics

¹Based on 2Q26 Epidiolex net product sales; ²Cannabidiol capsule formulation, if approved, for use in Epidiolex's currently approved indications: LGS, , TSC; ³Eeghen, AM, Thiele, EA, et al. Poster presented at: American Epilepsy Society 2024 Annual Meeting, December 6-10, 2024. Los Angeles, CA; ⁴Wrobel, N. Poster presented at: American Academy of Neurology 2025 Annual Meeting, April 5-9. San Diego, CA.



Now Approved in 1L HER2+ mGEA

Goal: Establish Ziihera as HER2-Targeted Agent of Choice in 1L HER2+ GEA

1. Clinical Education & Differentiation

Establishing the new Standard of Care: Ziihera + tislelizumab as foundational backbone for 1L HER2+ mGEA, **independent of PD-L1 status**

2. Accelerated Market Access

Leveraging immediate reimbursement: Utilize established, permanent J-code eliminating barriers to launch and driving rapid formulary adoption

3. Commercial & Field Execution

Day-one mobilization: cross-functional teams **launched Ziihera upon FDA approval**; capitalize on significant account overlap with Ziihera in BTC and Zepzelca in SCLC


4. Seamless Patient Experience

Frictionless onboarding: Activating comprehensive **JazzCares support services**; ensure zero barriers to patient access

Zanidatamab: Updated Peak Sales Opportunity of \$3-\$5B

Drivers of Peak Sales Increase:

- Approvals in BTC and GEA, derisked investments in existing studies
- Additional registrational trials planned in CRC, NSCLC, and early gastric cancer
- Additional registrational opportunities in mBC, early breast cancer and with novel combinations, including TKIs



Modeyso: Strong Initial Uptake and Early Launch Success

1

Disease State Awareness & Education



CNS WHO Grade 4 glioma¹
The most aggressive form of glioma




Invariably lethal with rapid mortality
Median OS: ~1 year from diagnosis²⁻⁵ and <6 months after recurrence⁶



Limited surgical options and no approved therapies for H3 K27M-mutant diffuse midline glioma^{7,8}

2

Branded Campaign Launch



First and only FDA-approved treatment for recurrent H3 K27M-mutant diffuse midline glioma

3

Launch Exceeding Expectations



Strong HCP awareness and focus on testing driving increasing breadth of adoption



Strong engagement with community oncologists; >600 patients have received Modeyso⁹



\$48M in 2Q26 net product sales
\$500M+ in U.S. peak sales potential

¹Louis DN et al. Neuro Oncol. 2021;23(8):1231–1251; ²Zheng L et al. Am J Surg Pathol. 2022;26:863-871; ³Vuong et al. Frontiers in Oncology March 2022; ⁴Mackay A et al. Cancer Cell. 2017;32(4):520-537; ⁵Ostrom QT et al. Neuro Oncol. 2023;25:799-807; ⁶Bagley et al Cancers 2025, 17(13), 2107; ⁷Nabors B et al. Neuro Oncol 25(12), 2114–2116, 2023; ⁸Gajjar A et al. J Natl Compr Canc Netw 2025;23(3):113–130; ⁹As of June 30, 2026.

Zepzelca: Opportunity to Redefine 1L ES-SCLC Treatment Paradigm



Donna

Former Zepzelca patient diagnosed with SCLC



FDA approved Zepzelca in combination with Tecentriq as first-line maintenance therapy for ES-SCLC in 4Q25

- Included in **NCCN Guidelines** as a **Category 1 preferred regimen**
- **Addresses significant unmet need:** IMforte trial results¹ shows mOS of **13.2 months** vs 10.6 months for atezolizumab alone from the point of randomization
- Potential to **increase duration of response** with earlier line patients
- In the U.S., there are **~30,000 1L SCLC patients**, with **~27,000** currently treated in the front-line², with 70% of 1L SCLC patients diagnosed with extensive-stage disease³

¹IMforte data presented at ASCO 2025, IMforte study done in collaboration with F. Hoffmann-La Roche Ltd; ²Approximate U.S. SCLC patient numbers, sources: SEER Cancer Stat Facts <https://seer.cancer.gov/statfacts/html/lungb.html>, accessed April 19, 2019, American Cancer Society, <https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html>, accessed April 12, 2019, Kantar Health Treatment Architecture SCLC July 2018, Jazz primary market research May 2019; ³SHS claims data ending September 2024; Tx Onc data ending October 2024; Onmark Unity Data ending October 2024; IntrinsiQ ION data ending October 2024.

Pipeline

Focused Investments in Promising
R&D Portfolio

Key Pipeline Programs

Key Clinical Programs	PHASE 1	PHASE 2	PHASE 3	PHASE 4 / REGULATORY	Recent / Upcoming Milestones
Zanidatamab	1L GEA (HERIZON-GEA-01)				Now Approved in 1L HER2+ mGEA; Arm B stat sig
	1L BTC (HERIZON-BTC-302)				
	Breast cancer patients post T-DXd (EmpowHER-BC-303)				Anticipate top-line data late 2027 / early 2028
	Neoadjuvant and adjuvant BC (EmpowHER-BC-208)				
	Neoadjuvant treatment of locally advanced BC (I-SPY2)				
	Pivotal trial for HER2+ solid tumors (DiscovHER-Pan-206)				
Dordaviprone	1L H3 K27M-mutant diffuse glioma (ACTION)				Anticipate interim OS data in 1H27
JZP3507 (ONC206)	Advanced Pheochromocytoma and Paraganglioma (PCPG)				
	Meningioma				
JZP815	RAF & RAS mutant tumors				
JZP898	Solid tumors				
Epidiolex (cannabidiol oral solution)	Focal-onset seizures				
	Developmental and epileptic encephalopathy (DEE)				New trial
	Adults with Lennox-Gastaut syndrome (LGS) ¹				New trial
Cannabidiol capsule formulation	Juvenile myoclonic epilepsy (JME) ²				New trial
	Capsule formulation				NDA submitted
JZP047	Absence Epilepsy				Initiated Phase 1 in healthy participants

¹Phase 2/3 trial utilizing cannabidiol capsule formulation; ²Phase 3b/4 trial.



Robust Ongoing Zanidatamab Development Program

	PHASE 1	PHASE 2	PHASE 3	RECENT / UPCOMING MILESTONES
1L GEA (HERIZON-GEA-01)				Now Approved; Arm B stat sig
1L BTC (HERIZON-BTC-302)				1L BTC confirmatory trial
Metastatic breast cancer (mBC) patients post T-DXd (EmpowHER-BC-303)				Anticipate top-line data late 2027 / early 2028
Pivotal trial for HER2+ solid tumors (DiscovHER-Pan-206)				Pivotal trial supporting potential pan-tumor indication
Neoadjuvant and adjuvant BC (EmpowHER-BC-208)				Early breast cancer trial
Neoadjuvant treatment of locally advanced BC (I-SPY2)				Collaborative I-SPY2 trial for early breast cancer
Open-label trial in early-stage, low-risk, HER2+ breast cancer				Collaborative trial with MD Anderson Cancer Center for early breast cancer
Paclitaxel and ramucirumab combination in HER2+ advanced GEA				Collaborative trial with Canadian Cancer Trials Group for GEA
Pembrolizumab and chemotherapy combination in HER2+ GEA				Collaborative ZANGEA trial for 1L GEA in combination with pembrolizumab
Neoadjuvant /adjuvant HER2+ GEA (AACR-ADOPT-GEA)				Platform trial assessing potential of organ sparing for zanidatamab combinations
Phase 1/1b I-SPY in breast cancer				Collaborative Pre I-SPY trial for breast cancer in combination with tucatinib
Zongertinib combination				Collaborative trial with Boehringer Ingelheim's novel HER2 TKI
IAM1363 combination				Collaborative trial with lambic's brain-penetrant HER2 small-molecule TKI



Financial Performance

**Financial Strength and Discipline
Enables Future Growth**

2Q26 Financial Results

Continued Commercial Execution + Financial Discipline

	2Q26	2Q25	Key Commentary
Total Revenues	\$1,208.3M	\$1,045.7M	16% increase primarily driven by higher Xywav, Modeyso, Epidiolex, and Zepzelca revenues
Non-GAAP Gross Margin ¹	92.1%	92.7%	Slight decrease primarily due to royalties on Zepzelca and Modeyso
Non-GAAP SG&A ¹	\$343.2M	\$310.3M	11% increase driven by investments in Modeyso and zanidatamab 1L GEA as well as in building key commercial capabilities
Non-GAAP R&D ¹	\$184.9M	\$167.0M	11% increase driven by higher clinical study costs, primarily related to zanidatamab
Non-GAAP Effective Tax Rate ¹	15.8%	(9.1)%	2Q26 reflects changes in expected geographic mix of income and expenses; 2Q25 includes impact of Chimerix Acquisition
Weighted-Average Diluted Shares	69.4M	61.2M	Increase includes accounting effect of higher stock price on employee stock compensation plans and convertible notes
Non-GAAP EPS/LPS ¹	\$5.71	\$(8.25)	Includes acquired IPR&D charges of \$0.94 and \$14.75 per share in 2Q26 and 2Q25, respectively

¹Non-GAAP Adjusted Gross Margin, SG&A expenses, R&D expenses, ETR, and EPS/LPS are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures" and reconciliation tables in the Appendix.



2026 Financial Guidance

Raising Revenue and Updating Expense Guidance¹

	Updated 2026 Guidance (as of August 3, 2026)	Prior Guidance (as of May 5, 2026)	Key Commentary
Total Revenues	\$4.60 - \$4.75B	\$4.25 - \$4.50B	- Continue to expect double-digit growth for combined rare oncology + epilepsy revenue - Now expect double-digit growth for Xywav sales - Now expect \$2.025B - \$2.125B in rare sleep revenue²
Non-GAAP Gross Margin ³	90% - 91%	90% - 91%	
Non-GAAP SG&A ³	\$1.33 - \$1.37B	\$1.26 - \$1.32B	- Updated guidance reflects targeted investments to drive further growth of Xywav and Epidiolex and to build key capabilities - Reduction from prior year due to 2025 legal settlements
Non-GAAP R&D ³	\$725 - \$775M	\$725 - \$775M	
Non-GAAP Effective Tax Rate ³	11.5% - 13.5%	11.5% - 13.5%	
Weighted-Average Diluted Shares	69 - 70M	66 - 67M	Increase vs 2025 and prior guidance primarily driven by the effect of higher stock price on convertible notes and employee stock compensation plans

¹Guidance provided by Jazz Pharmaceuticals as of August 3, 2026; ²Rare sleep franchise includes Xywav, Xyrem and high-sodium oxybate AG royalty revenues; ³Non-GAAP Adjusted Gross margin, SG&A expenses, R&D expenses, and ETR are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures" and reconciliation table in the Appendix.



Well Positioned to Succeed in Rare Disease

**Research and
Development**

Commercial

**Corporate
Development**

**Strong Financial
Position**

\$1.2B

Total revenues¹

\$824M

Cash from operations²

\$2.2B

Cash, cash equivalents,
and investments³

¹For the quarter ended June 30, 2026; ²For the six months ended June 30, 2026; ³As of June 30, 2026.



Appendix

Glossary

Acronym	Definition
1L	First-line
2L	Second-line
Actio	Actio Biosciences, Inc.
AG	Authorized generic
ANI/ANL	Adjusted net income/Adjusted net loss
B	Billions
BC	Breast cancer
BTC	Biliary tract cancer
Chimerix Acquisition	Our acquisition of Chimerix on April 21, 2025
CNS	Central Nervous System
CRC	Colorectal cancer
DEE	Developmental and Epileptic Encephalopathy
DS	Dravet syndrome
EPS/LPS	Earnings per share/Loss per share
ES	Extensive-stage
ETR	Effective Tax Rate
FDA	U.S. Food and Drug Administration
GAAP	Generally accepted accounting principles
GEA	Gastroesophageal adenocarcinoma
HCP	Healthcare provider
HER2	Human epidermal growth factor receptor 2
IH	Idiopathic hypersomnia

Acronym	Definition
IPR&D	In-process research and development
JME	Juvenile myoclonic epilepsy
LGS	Lennox-Gastaut syndrome
M	Millions
NCCN	National Comprehensive Cancer Network
NDA	New drug application
NSCLC	Non-small cell lung cancer
OS	Overall survival
PD-L1	Programmed Death-Ligand 1
R&D	Research and development
RAF	Rapidly accelerated fibrosarcoma
RAS	Rat Sarcoma Virus
SCLC	Small-cell lung cancer
SG&A	Selling, general and administrative
TCE	T-cell engaging
T-DXd	Trastuzumab deruxtecan
TKI	Tyrosine kinase inhibitors
TSC	Tuberous sclerosis complex
WHO	World Health Organization
YoY	Year-over-year, 2Q26 vs. 2Q25
YTD	Year-to-date



Reconciliation of GAAP Reported to Non-GAAP Adjusted Information¹

In millions, except per share amounts (unaudited)	Three Months Ended June 30,			
	2026 Net Income	Diluted EPS	2025 Net Loss	Diluted LPS
GAAP reported	\$192.8	\$2.78	\$(718.5)	\$(11.74)
Intangible asset amortization	170.0	2.45	162.1	2.65
Share-based compensation expense	73.3	1.06	64.5	1.05
Acquisition accounting inventory fair value step-up	16.6	0.24	37.1	0.61
Integration related expenses ²	—	—	9.4	0.15
Income tax effect of above adjustments	(56.3)	(0.82)	(59.4)	(0.97)
Non-GAAP adjusted¹	\$396.4	\$5.71	\$(504.8)	\$(8.25)
Weighted-average ordinary shares used in diluted per share calculations – GAAP and non-GAAP ¹	69.4		61.2	

¹Non-GAAP Adjusted net income (loss) (and the related per share measure) are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”; ²Integration related expenses with respect to the Chimerix Acquisition.



Reconciliation of GAAP Reported to Non-GAAP Adjusted Information¹

(In millions, except percentages)	Three Months Ended June 30,	
	2026	2025
GAAP gross margin on total revenues	90.4 %	88.9 %
Acquisition accounting inventory fair value step-up	1.3 %	3.5 %
Share-based compensation expense	0.4 %	0.3 %
Non-GAAP gross margin ¹ on total revenues	92.1 %	92.7 %
GAAP SG&A expenses	\$389.2	\$358.4
Share-based compensation expense	(46.0)	(41.0)
Integration related expenses ²	—	(7.1)
Non-GAAP SG&A expenses ¹	\$343.2	\$310.3
GAAP R&D expenses	\$207.5	\$189.9
Share-based compensation expense	(22.6)	(20.6)
Integration related expenses ²	—	(2.3)
Non-GAAP R&D expenses ¹	\$184.9	\$167.0
GAAP ETR	8.6 %	2.3 %
Income tax effect of GAAP to non-GAAP reconciling items	7.2 %	(11.4)%
Non-GAAP ETR ¹	15.8 %	(9.1)%

¹Non-GAAP Adjusted Gross Margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures"; ²Integration related expenses with respect to the Chimerix Acquisition.



Reconciliation of GAAP to Non-GAAP Adjusted¹ 2026 Guidance

(In millions, except percentages)	Projected Range	
	Low	High
GAAP gross margin on total revenues	89 %	90 %
Acquisition accounting inventory fair value step-up	1 %	1 %
Non-GAAP gross margin ¹ on total revenues	90 %	91 %
GAAP SG&A expenses	\$1,506	\$1,556
Share-based compensation expense	(176)	(186)
Non-GAAP SG&A expenses ¹	\$1,330	\$1,370
GAAP R&D expenses	\$818	\$873
Share-based compensation expense	(93)	(98)
Non-GAAP R&D expenses ¹	\$725	\$775
GAAP ETR	0 %	10 %
Income tax effect of GAAP to non-GAAP reconciling items	11.5 %	3.5 %
Non-GAAP ETR ¹	11.5 %	13.5 %

¹Non-GAAP Adjusted Gross Margin, SG&A expenses, R&D expenses and ETR are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures".

